Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based drug discovery firm Synairgen has announced new research signaling a second indication for its inhaled interferon beta program in chronic obstructive pulmonary disease.
Subscribe to our email newsletter
The common cold (rhinovirus) is a major factor behind the worsening of chronic obstructive pulmonary disease (COPD) symptoms and resultant hospitalizations. Preliminary data presented by Synairgen at this year's American Thoracic Society conference, and derived from its in vitro models of airway cells from smokers, indicates that these people are unusually susceptible to the common cold virus and that the addition of interferon beta (IFN-beta) improves their natural defence system.
This suggests that IFN-beta treatment has the potential to reduce the likelihood of hospitalization of COPD patients as a consequence of common cold infections. Synairgen will now utilize its in vitro models of COPD to further validate this target.
The company's inhaled IFN-beta program for asthma is currently in phase I trials. It is anticipated that the successful completion of these trials will help to accelerate clinical studies for the additional indication.
“With the addition of COPD to our interferon program, we now have two distinct indications where successful drugs could achieve annual sales in excess of $1 billion,” remarked Synairgen managing director Richard Marsden.